<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="214554">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00292747</url>
  </required_header>
  <id_info>
    <org_study_id>L_9134</org_study_id>
    <nct_id>NCT00292747</nct_id>
  </id_info>
  <brief_title>Drotaverine in Dysmenorrhoea Treatment</brief_title>
  <official_title>Comparison of the Efficacy and Tolerability of Drotaverine 80 mg, Ibuprofen 400 mg and Their Combination in a Calendar Packaging for the Treatment of Primary and Secondary Dysmenorrhoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The aim of the study is to show that the combination of drotaverine 80mg and ibuprofen 400
      mg is more effective and as well-tolerated as ibuprofen 400 mg or drotaverine 80 mg
      administered alone, in the treatment of primary and secondary dysmenorrhoea.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    early termination due to loss of interest and low enrollment of patient
  </why_stopped>
  <start_date>May 2005</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reponse rate in each treatment arm: proportion of patients having pain intensity score 0 or 1 at hour 2 after the first drug intake.</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>480</enrollment>
  <condition>Dysmenorrhea</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drotaverine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of at least 6 months of dysmenorrhea, with presence of moderate to severe
             pain in each of the last 3 cycles

          -  With regular menstrual cycles (25-35 days)

          -  Using an adequate barrier contraception method (except for virgins)

        Exclusion Criteria:

          -  Evidence of clinically relevant gynecological, cardiovascular, hematologic, hepatic,
             gastrointestinal, renal, pulmonary, endocrinologic, neurologic or psychiatric
             disease, based on a clinical assessment and routine laboratory investigations

          -  Proven hypersensitivity to drotaverine hydrochloride or ibuprofen or proven
             intolerance to lactose

          -  Any described contraindication to either drotaverine hydrochloride or ibuprofen (see
             Summary of Product Characteristics)

          -  Oestro-progestative contraception within the last 2 months

          -  Regular use of sedative, hypnotics, tranquillizers or any other addictive agents

          -  History or evidence of acute or chronic alcohol abuse

          -  Heavy smoking (&gt; 10 cigarettes/day)

          -  Need of a permanent treatment with other antispasmodics and/or analgesic agents
             during the trial

          -  Lactation

          -  Pregnancy

          -  Participation in another clinical trial in the last 3 months prior to the start of
             this study

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>László Erős, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi-aventis, Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <lastchanged_date>November 14, 2008</lastchanged_date>
  <firstreceived_date>February 15, 2006</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Drotaverin</mesh_term>
    <mesh_term>Papaverine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
